Pharmaceutical

Sonnet BioTherapeutics secures EU patent for FHAB technology

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.

Jan 30, 2025 - 06:00
Sonnet BioTherapeutics secures EU patent for FHAB technology
Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.
Read the original article

Tags:

Previous Article

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD

Next Article

Will European PFAS ban disrupt pharma supply chains?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: NYU launched private ChatGPT for its health data, and set its staff loose to experiment

STAT+: NYU launched private ChatGPT for its health data...

Aug 25, 2023

Opinion: The U.S. must raise federal alcohol taxes to address the alarming rise in alcohol use

Opinion: The U.S. must raise federal alcohol taxes to a...

Dec 21, 2023

Why doesn’t the U.S. have more Black midwives?

Why doesn’t the U.S. have more Black midwives?

Sep 18, 2023